Jiangsu has 14 pharmaceutical companies in the list of the top 100 pharmaceutical 4 enterprises main revenue of more than 10 billion

"Pharmaceutical Network Industry Dynamics" Recently, the 2019 China Pharmaceutical Industry Top 100 List was announced at the 2020 National Pharmaceutical Industry Information Annual Meeting, the top 100 enterprises continued to maintain a strong growth momentum, the main business revenue reached 929.64 billion yuan, a growth rate of 10.7%.
it is learned that in this list, Jiangsu has 14 pharmaceutical companies into the list, including 4 pharmaceutical companies, namely Yangzijiang Pharmaceuticals, Hengrui Pharmaceuticals, Zhengda Tianqing, AstraZene half of the main revenue of more than 10 billion yuan.
Yangzijiang Pharmaceuticals ranked first in the top 100 pharmaceutical list Yangzijiang Pharmaceuticals founded nearly 50 years ago, with the national strategy of resonance, adhere to the main pharmaceutical industry, carry forward the "for parents pharmaceutical, pharmaceutical for relatives" quality culture, to research and development innovation to meet the people's health needs.
2019, in the face of the severe and complex macro environment, the pharmaceutical market volatility, rapid institutional changes in the new situation, Yangzijiang Pharmaceutical Group scientific research and judgment "time" and "potential", dialectical grasp of "dangerous" and "machine", adhere to high-quality development non-stop.
data show that in 2019, Yangzijiang Pharmaceutical Group achieved sales, profits and taxes increased by 11.94 percent and 16.2 percent year-on-year, respectively, the comprehensive strength of a new high, in this pharmaceutical top 100 list, Yangzijiang Pharmaceuticals ranked first.
In the future, Yangzijiang Pharmaceuticals will continue product innovation, quality innovation, technological innovation, management innovation, deepen supply-side structural reform, to establish an international advanced drug production quality management system as the strategic direction of quality, to build Longfengtang Chinese medicine industrial park, the implementation of standardized cultivation of Traditional Chinese medicine, the establishment of the whole process of Chinese medicine traceability system, high starting point layout of large health industry, accelerate the pace of green manufacturing, intelligent manufacturing, fulfill social responsibility, stimulate high-quality development of the momentum.
Hengrui Pharmaceuticals ranked among the top ten Hengrui Pharmaceuticals gradually established and improved the sales management system of the division, forming the tumor, imaging, surgical anesthesia, integrated products division, as well as the strategic development division.
2019, Hengrui Pharmaceuticals achieved operating income of 23.289 billion yuan, up 33.7% YoY, and net profit attributable to shareholders of listed companies was 5.328 billion yuan, up 31.05% YoY.
ranked 10th in this 100-strong list, making it into the top 10 for the first time.
note that in 2019, the company invested 3,896 million yuan in research and development, up 45.9% YoY, accounting for 16.73 percent of total sales revenue.
separate data show that in the first half of 2020, Hengrui Pharmaceuticals achieved revenue of RMB11,309 million, up 12.79% YoY; Swiss medicine as a domestic medicine "one brother", not only in the domestic market, recently, Hengrui Pharmaceuticals announced that it received the U.S. Food and Drug Administration (FDA) notice, Hengrui to the U.S. FDA declared the right metomide sodium hydrochloride injection application has been approved, can be produced and sold in the U.S. market.
, Hengrui Pharmaceuticals has 19 products, including injections, oral preparations and inhalation anesthetics, have been approved for sale in Europe, america and Japan.
Zhengda Tianqing ranked 16th in the top 100 list it is understood that Zheng tianqing for 6 consecutive years was selected in the top 100 list of the top 20, highlighting the enterprise in the face of pressure and challenges, to scientific and technological innovation as a support to brand quality as a guarantee, to people's livelihood demand-oriented, innovation and change, pioneering and enterprising strength.
Since 2019, Zhengtianqing research and development technology platform is increasingly advanced, chemical drugs, biological drugs, two-pronged approach to promote innovative drug research and development; Extensive layout, research and development efficiency continues to improve, Budinade (fast-track), fluovis group (clear can be), Aza cytoside (viscera) and other key products listed, "clear can be based" for the Three Places in China and Europe listed, the first domestic imitation, "fast-track" for China's treatment of slow-blocking lung, asthma, the field of the first atomizing agent-type generic drugs.
AstraZeneta's main revenue of more than 10 billion yuan AstraZene in the field of cancer, respiratory, cardiovascular and other traditional advantages of diseases have established a new product core, and are also in various fields close to clinical needs of the hot target new drugs.
total revenue of $24,384 million in 2019, up 10% year-on-year.
China revenue was $4.880 billion, up 35 per cent year-on-year and accounting for 20.7 per cent of AstraZeneta's global revenue.
has become a performing foreign drug company in the Chinese market and will continue to hit new highs.